| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/07/2004 | CA2107516C Antithrombin iii preparation |
| 12/02/2004 | WO2004104493A2 Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
| 12/02/2004 | WO2004104492A2 Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| 12/02/2004 | WO2004104491A2 Percussively ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| 12/02/2004 | WO2004104490A1 Self-contained heating unit and drug-supply unit employing same |
| 12/02/2004 | WO2004104021A2 Controlled release of active agents utilizing repeat sequence protein polymers |
| 12/02/2004 | WO2004104020A2 Repeat sequence protein polymer active agent conjugates, methods and uses |
| 12/02/2004 | WO2004103409A1 Antitumor agent and process for producing the same |
| 12/02/2004 | WO2004103408A2 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
| 12/02/2004 | WO2004103382A1 Combination chemotherapy comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex |
| 12/02/2004 | WO2004103363A1 Use of poly-amminopyrrolecarboxamides alone or in combination with a cyclodextrin in the prophylaxis and treatment of animal parasitosis |
| 12/02/2004 | WO2004103362A1 Formulation of the total anhydrides of cantharidin for the treatment and prevention of severe acute respiratory syndrome infections and the preparation thereof |
| 12/02/2004 | WO2004103343A1 Dimeticone-containing sustained formulation |
| 12/02/2004 | WO2004103342A2 Injectable sustained release compositions |
| 12/02/2004 | WO2004103272A2 Improved cytotoxic agents comprising new maytansinoids |
| 12/02/2004 | WO2004103233A1 Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |
| 12/02/2004 | WO2004096263A3 Human serum albumin-free stabilized interferon liquid formulations |
| 12/02/2004 | WO2004082707A3 Stabilisation of growth hormones in solution |
| 12/02/2004 | WO2004078215A3 Use of antibody conjugated deoxycytidine kinase for adept |
| 12/02/2004 | WO2004069211A3 Affinity proteins for controlled application of cosmetic substances |
| 12/02/2004 | WO2004065440A3 Cationic graft-copolymer for non-viral gene delivery vector |
| 12/02/2004 | WO2004056338A9 Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
| 12/02/2004 | WO2004043347A3 Calcitonin drug-oligomer conjugates, and uses thereof |
| 12/02/2004 | WO2004041198A3 Heat pasteurized liquids containing glucosamine |
| 12/02/2004 | WO2004017897A3 Aripiprazole complex formulation and method |
| 12/02/2004 | WO2003092640A8 Cosmetic product comprising at least one water-soluble copolymer which contains (meth)acrylamide units |
| 12/02/2004 | WO2003064665A3 Viral vector |
| 12/02/2004 | WO2003039452A3 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| 12/02/2004 | WO2003017938A3 Conjugates targeted to target receptors |
| 12/02/2004 | US20040243097 Antiproliferative drug and delivery device |
| 12/02/2004 | US20040242860 Compositions and methods for the diagnosis and treatment of tumor |
| 12/02/2004 | US20040242730 Stabilized particle dispersions containing nanoparticles |
| 12/02/2004 | US20040242729 Contains dispersed phase that comprises particles dispersed in the continuous phase; continuous phase comprises a liquid continuous phase and surface-modified inorganic nanoparticles; a pharmaceutical dispersion for administration to mammals |
| 12/02/2004 | US20040242646 Dantrolene as anesthetics for pumping injection |
| 12/02/2004 | US20040242640 Dual-release compositions of a cyclooxygenase-2 inhibitor |
| 12/02/2004 | US20040242626 Nasal delivery of apomorphine |
| 12/02/2004 | US20040242625 Nasal delivery of apomorphine |
| 12/02/2004 | US20040242624 Nasal delivery of apomorphine |
| 12/02/2004 | US20040242570 Conjugated psychotropic drugs and uses thereof |
| 12/02/2004 | US20040242546 Compositions and method for treating infection in cattle and swine |
| 12/02/2004 | US20040242541 killing insects such as lice, ticks or fleas by applying low surface tension lubricants; topical |
| 12/02/2004 | US20040242538 Method to improve complexation efficacy and produce high-energy cylodextrincomplexes |
| 12/02/2004 | US20040242536 controlled-release mixtures of plant extracts, gelation polymers and drugs such as ximelagatran, used for prophylaxis of cardiovascular disorders |
| 12/02/2004 | US20040242534 Lyophilized powder of lentinan and the process of preparation thereof |
| 12/02/2004 | US20040242514 Xenogenic oligo or/and polyribonucleotides as agents for the treatment of malignant tumours |
| 12/02/2004 | US20040242507 Topical formulations of a lipophilic anthracycline with a second active ingredient and carrier; antiproliferative agents for skin and mucus membrane disorders; side effect reduction in psoriasis treatment with valrubicin |
| 12/02/2004 | US20040242506 Formed from paroxetine hydrochloride and ammonium glycyrrhyzinate by precipitation, spray, vacuum or freeze drying, or evaporation to glass; solid or oil; masks the bitter taste of paroxetine and has a distinctive licorice flavor; antidepressants; Parkinson's disease |
| 12/02/2004 | US20040242497 Ammonium glycyrrhyzinate masks the bitter taste of paroxetine hydrochloride and has a distinctive licorice flavor; dispersable powders or tablets; antidepressants; Parkinson's disease |
| 12/02/2004 | US20040242489 Method for improving stability of a bone-connecting implant |
| 12/02/2004 | US20040242478 5-cnac as oral delivery agent for parathyroid hormone fragments |
| 12/02/2004 | US20040242476 Peptide and analogs thereof having an amino acid sequence corresponding to the second extracellular domain of a mammalian occludin; may be administered orally or parenterally |
| 12/02/2004 | US20040242460 Using fatty acid, storage stable |
| 12/02/2004 | US20040242416 Compositions and methods for intracellular delivery |
| 12/02/2004 | US20040241855 Polyoxyethylene glycol (peg)-lipid-immunogen conjugates; for incorporation into liposomes to enhance intracelllar delivery of nucleic acids and drugs |
| 12/02/2004 | US20040241806 G-CSF polypeptides and conjugates |
| 12/02/2004 | US20040241772 Solid composition cantaining bacillus-type non-pathogenic bacterial spores |
| 12/02/2004 | US20040241703 Using tumor specific marker to diagnose and treat cell proliferative disorders; immunodiagnostics |
| 12/02/2004 | US20040241253 Especially animal or vegetable extracts, containing one or more saccharides such as sugar alcohols to prevent precipitation and effect storage stability over a long period of time; pH is adjusted to 4.5-5.5 |
| 12/02/2004 | US20040241248 Crosslinking the carboxylic acid groups in a glycosaiminoglycan with a primary amine in a lipid to form particles that can be used to encapsulate various drugs, especially chemotherapeutic agents |
| 12/02/2004 | US20040241247 Foaming a fluid mixture of a polymer and a liquid diluent with a gas and contacting with foam produced with solid particles of an average size of less than 2500 micrometers; either the fluid or the particles contain a drug; may be pressed to form a tablet |
| 12/02/2004 | US20040241245 Compositions and methods for treatment of premature ejaculation |
| 12/02/2004 | US20040241244 Neuronal growth enhancement by prostaglandin compositions and methods |
| 12/02/2004 | US20040241243 Angiogenesis promotion by prostaglandin compositions and methods |
| 12/02/2004 | US20040241240 A copolymer of N-vinyl-2-pyrrolidone with e.g., ethylhexyl acrylate and 1,6-hexanediol diacrylate, enhances absorption of a hardly soluble drug such as one having an ergoline skeleton, e.g., a pergolide or a bromocriptine; improved skin permeability |
| 12/02/2004 | US20040241239 Mixed complexes for masking the taste of bitter active substances |
| 12/02/2004 | US20040241236 shell provides a delay of greater than one hour for the onset of dissolution of the active ingredient upon contacting of the dosage form with a liquid medium such as water or gastrointestinal fluids, and the delay is independent of the pH |
| 12/02/2004 | US20040241235 Core of drug and binder having at least three successive coating layers starting from the core: a delayed or sustained release polymeric coating; a hydrophobic coating containing a waxy compound; and another polymeric coating having a complementary release function and conditioning the suspension medium |
| 12/02/2004 | US20040241233 Sustained release heterodisperse hydrogel systems- amorphous drugs |
| 12/02/2004 | US20040241232 Comprising inhalable medicament particles having a mass median aerodynamic diameter no greater than 10 mu m and 50% of a non-respirable excipient fraction comprising low density excipient particles having an aerodynamic diameter greater than 10 mu m and a geometric diameter greater than 30 mu m |
| 12/02/2004 | US20040241231 Carrier matrix containing a plurality of particles having open pores or capillary spaces which serve as active substance reservoirs and contain at least one active substance; small thickness |
| 12/02/2004 | US20040241222 Lipid-polymer-conjugates compositions |
| 12/02/2004 | US20040241219 System comprising back layer, protective layer and at least one active-compound-containing polymer matrix comprising a polyacrylate which contains extremely reduced number of functional groups; in one embodiment polyacrylate is free of hydroxyl and/or carboxyl groups |
| 12/02/2004 | US20040241218 Transdermal patch, wherein dosage form includes at least one activating agent and at least one inactivating agent where inactivating agent is released only when dosage form is solubilized, opened, chewed and/or cut apart, but it is not transdermally delivered to patient |
| 12/02/2004 | US20040241217 Method for administration of immune modulators in systemic and localized immune disorders |
| 12/02/2004 | US20040241208 Comprising an active ingredient and a carbohydrate, at least a portion of which carbohydrate is crystallized and has an average particle size of 2 to 35 microns, composition having a moisture content of 10 to 13 percent; soft tablet |
| 12/02/2004 | US20040241205 capsules comprising biocompatible silica sol-gel matrices that encapsulate chemical intermediates or prodrugs that convert when contacted with tissues and/or fluids; grafting encapsulated L-amino acid decarboxylase in the brain to convert L-dopa to dopamine for prophylaxis of Parkinson's disease |
| 12/02/2004 | US20040241204 Sustained release pharmaceutical composition |
| 12/02/2004 | US20040241203 Porous matrix comprising cross-linked particles |
| 12/02/2004 | US20040241187 An inactivated, disrupted influenza virus preparation of a hemagglutinin antigen stabilised by alpha-tocopherol succinate in the absence of thiomersal or at low levels of thiomersal; hemagglutinin detectable by a single radial immunoassay (SRID); mercury-free preservative; administering by any route |
| 12/02/2004 | US20040241174 Drug conjugate composition |
| 12/02/2004 | US20040241173 Formed via hydrolysis; antibiotic resistance; may contain penicillins, cephalosporins, quinolones, fluoroquinolones, macrolides, lincosamines, carbepenems, conobactams, aminoglycosides, glycopeptides, tetracyclines, sulfonamides, rifampin, oxazolidonones, and streptogramins |
| 12/02/2004 | US20040241172 Pretargeting methods and compounds |
| 12/02/2004 | US20040241171 Leukocyte inactivation module |
| 12/02/2004 | US20040241168 Compositions and methods for the treatment and clinical remission of psoriasis |
| 12/02/2004 | US20040241158 Targetting antibodies containing haptens, cleaning agent, and drug delivery agent; tissue-directed therapy; solid phase synthesis |
| 12/02/2004 | US20040241155 Dilution resistant viscoelastic compositions |
| 12/02/2004 | US20040241135 Therapeutic compositions including bio-availability enhancers |
| 12/02/2004 | US20040241101 Stabilized aerosol dispersions |
| 12/02/2004 | US20040241099 Foamable pharmaceutical compositions and methods for treating a disorder |
| 12/02/2004 | US20040241094 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| 12/02/2004 | US20040241093 Mixture of hydrocolloid stabilizer and sugar osmosis agent; adjust viscosity of body fluid |
| 12/02/2004 | US20040241088 Method for evaluating the efficacy of certain cancer treatments |
| 12/02/2004 | US20040238781 Using genistein; preadministering before exposure to radiation; prevent tissue damage |
| 12/02/2004 | DE202004009180U1 Formulation comprising glycine-containing gel, useful, by external or internal application, for treatment or prevention of e.g. allergy, sunburn and stress |
| 12/02/2004 | CA2526478A1 Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
| 12/02/2004 | CA2526475A1 Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| 12/02/2004 | CA2526470A1 Percussively ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| 12/02/2004 | CA2526432A1 Self-contained heating unit and drug-supply unit employing same |
| 12/02/2004 | CA2526289A1 Combination chemotherapy comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex |
| 12/02/2004 | CA2525840A1 Ovr115 antibody composition and methods of use |